The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.
Known prior diagnosis of myelodysplasia (MDS)
High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and/or high-risk molecular abnormalities (e.g., TP53)
Requirement for 2 or more inductions to achieve CR1
Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and/or gene therapy or cell therapy)
Chloroma >2 cm.
Active and uncontrolled infection (bacterial/fungal/viral) at time of transplant.
HIV infection.
Seropositivity for HTLV-1.
Memorial Sloan Kettering Cancer Center
Lead sponsor